There is a growing demand for public health insurance programmes to reimburse high-cost medicines, including those that do not represent good value-for-money. This demand is likely to inhibit financial sustainability, given the growth of new technologies and public demands for expanded access to car

Yot Teerawattananon,1 Sripen Tantivess,1 Pitsaphun Werayingyong,1 Pritaporn Kingkaew,1 Nilar Tin,2 San San Aye,3 Phone Myint3 Abstract Introduction: In 2010, with financial support from the Global Alliance for Vaccine and Immunization’s Health System Strengthening programme, the Government of

In the Philippines, use of HTA is not completely new; there have been prior efforts to institutionalize a fair and systematic process of generating policy-relevant evidence to inform coverage of health services, such as listing of drugs in the national formulary and new benefits in the national soci

17-2-021-2559(2)economic impact,health impact,health technology,HITA,HITAP,HTA,Unsafe food,การประเมินเทคโนโลยีและนโยบายด้านสุขภาพ,ประเมินผลกระทบ,อาหารไม่ปลอดภัย

In 2018-19, HITAP collaborated with the University of Strathclyde to conduct a study on assessing the value of HTA agencies as part of the Evaluating the Value of a Real-world HTA agency (EVORA) project. The three outputs from this study are an Excel-based simulation model, a logic model on the impact of HTA agencies and a review of literature. The

As countries develop their health systems on the path to Universal Health Coverage (UHC) (#LeaveNoOneBehind), many countries are experimenting with the development of a health technology assessment (HTA) agency in order to set priorities for health benefit packages, make go/no go decisions about

Generic reference cases for economic evaluation (EE) of “cure-based” health technologies may not fit into the new healthcare paradigm of precision medicine (PM). Current EE approaches were challenged by the complex evolving decision space of PM, lack of clinical evidence due to small patient cluster

\"First Step”, a program evaluation report, assessing HITAP’s two-year efforts and providing recommendations for further development of HITAP. This program evaluation was conducted by four external evaluators including Prof. John Cairns, Dr. Kalipso Chalkidou, Prof. Paibul Suriyawongpaisal, and Dr. Jirawat Panpiemras. Moreover, Prof. Mark Sculp

Since 2013, the HITAP International Unit (HIU) has been providing technical support to various developing countries such as Indonesia, Vietnam, Bhutan, and India by sharing the Thai experience in generating and using health technology assessment (HTA) to inform policy decisions. HITAP works in colla

As we approach the end of an unprecedented year, the approval of select COVID-19 vaccines by stringent regulatory authorities and programmatic roll-out has been cause for optimism. However, it is imperative to assure equitable access to those in need in all regions of the world as a core component o